Will Lawn

Senior Lecturer in Clinical Psychopharmacology at King's College London

Data updated

Papers

6 publications

Trials

0 clinical trials

Research Footprint

Will Lawn appears in 6 tracked papers (2015–2022), most studied alongside Ketamine, Psilocybin and Ayahuasca, across Substance Use Disorders (SUD), Depressive Disorders and Alcohol Use Disorder (AUD).

Most-cited paper: Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder (164 citations).

Frequent co-authors: Celia Morgan, Valerie Curran and David Nutt.

Background & Research

Will Lawn is a clinical psychopharmacology researcher based in the UK, previously associated with University College London and now at King's College London. His work has focused on the effects and therapeutic potential of psychoactive drugs, including cannabis, ketamine, psilocybin, MDMA, and ayahuasca, especially in addiction and depression research. He has authored clinical and observational studies examining both subjective drug effects and potential mechanisms of psychedelic-assisted therapy.

Key Impact

He is a prominent psychopharmacology researcher whose work spans ketamine, psilocybin, MDMA, and ayahuasca in addiction and mental health.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

13 collaborators· click a node to visit their profile

Full network →

Compounds

KetaminePsilocybinAyahuascaMDMAIbogaineLSDDMT

Topics

Substance Use Disorders (SUD)Depressive DisordersAlcohol Use Disorder (AUD)Safety & Risk ManagementPublic Health, Prevention & Behaviour ChangeOpioid Use Disorder (OUD)SchizophreniaMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Anxiety DisordersPalliative & End-of-Life DistressInterpersonal Functioning & Social ConnectednessNeurocognitive Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Will Lawn is associated with.

King's College London

academic

The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.

View stakeholder →

University College London

academic

The Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.

View stakeholder →